9th Neuropsychiatric Drug Development Summit 2026

 

Despite recent Phase II and III setbacks, neuropsychiatric drug development is regaining momentum, driven by progress across neuroplastogens, muscarinics, psychedelics, and other emerging modalities, alongside increasing regulatory support and investment.

Learnings from recent failures are informing more resilient, biology‑first development strategies, with greater emphasis on patient stratification, biomarkers, and translational frameworks to address placebo effects, heterogeneity, and late‑stage attrition.

Bringing together 150+ senior leaders and 46+ speakers from leading pharma, biotech, and investment organisations, the 9th Neuropsychiatric Drug Development Summit serves as a key forum for advancing precision psychiatry and patient‑centred mental health innovation.

 

More Info

---

---